Brivudine is used for the treatment of herpes zoster in adult patients. It is taken orally once daily, in contrast to aciclovir, valaciclovir and other antivirals. A study has found that it is more effective than aciclovir, but this has been disputed because of a possible conflict of interest on part of the study authors.
Contraindications
The drug is contraindicated in patients undergoing immunosuppression or cancer therapy, especially with fluorouracil and chemically related drugs such as capecitabine and tegafur, as well as the antimycotic drug flucytosine, which is also related to 5-FU. It has not been proven to be safe in children and pregnant or breastfeeding women.
Brivudine interacts strongly and in rare cases lethally with the anticancer drug fluorouracil, its prodrugs and related substances. Even topically applied 5-FU can be dangerous in combination with brivudine. This is caused by the main metabolite, bromovinyluracil, irreversibly inhibiting the enzyme dihydropyrimidine dehydrogenase which is necessary for inactivating 5-FU. After a standard brivudine therapy, DPD function can be compromised for up to 18 days. This interaction is shared with the closely related drug sorivudine which also has BVU as its main metabolite. There are no other relevant interactions. Brivudine does not significantly influence the cytochrome P450 enzymes in the liver.
Pharmacology
Spectrum of activity
The drug inhibits replication of varicella zoster virus – which causes herpes zoster – and herpes simplex virus type 1, but not HSV-2 which typically causes genital herpes. In vitro, inhibitory concentrations against VZV are 200- to 1000-fold lower than those of aciclovir and penciclovir, theoretically indicating a much higher potency of brivudine. Clinically relevant VZV strains are particularly sensitive.
Brivudine is well and rapidly absorbed from the gut and undergoes first-pass metabolism in the liver, where the enzyme thymidine phosphorylase quickly splits off the sugar component, leading to a bioavailability of 30%. The resulting metabolite is bromovinyluracil, which does not have antiviral activity. BVU is also the only metabolite that can be detected in the blood plasma. Highest blood plasma concentrations are reached after one hour. Brivudine is almost completely bound to plasma proteins. Terminal half-life is 16 hours; 65% of the substance are found in the urine and 20% in the faeces, mainly in form of an acetic acid derivative, but also other water-soluble metabolites, which are urea derivatives. Less than 1% is excreted in form of the original compound.
Chemistry
The molecule has three chiral carbon atoms in the deoxyribose part all of which have defined orientation; i.e. the drug is stereochemically pure. The substance is a white powder.
Manufacturing
Main supplier is Berlin-Chemie, now part of Italy's Menarini Group. In Central America is provided by Menarini Centro America and Wyeth.
History
The substance was first synthesized by scientists at the University of Birmingham in the UK in 1976. It was shown to be a potent inhibitor of HSV-1 and VZV by Erik De Clercq at the Rega Institute for Medical Research in Belgium in 1979. In the 1980s the drug became commercially available in East Germany, where it was marketed as Helpin by a pharmaceutical company called Berlin-Chemie. Only after the indication was changed to the treatment of herpes zoster in 2001 did it become more widely available in Europe. Brivudine is approved for use in a number of European countries including Austria, Belgium, Germany, Greece, Italy, Portugal, Spain and Switzerland.
Etymology
The name brivudine derives from the chemical nomenclaturebromo-vinyl-deoxyuridine or BVDU for short. It is sold under trade names such as Bridic, Brival, Brivex, Brivir, Brivirac, Brivox, Brivuzost, Zerpex, Zonavir, Zostex, and Zovudex.
